Al-Samkari Hanny
Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Res Pract Thromb Haemost. 2025 Jul 22;9(5):102980. doi: 10.1016/j.rpth.2025.102980. eCollection 2025 Jul.
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy for solid tumors that results in increased bleeding risk and chemotherapy dose reductions, treatment delays, and agent discontinuation. Unlike other chemotherapy-induced cytopenias, CIT remains without any licensed therapies in most of the world. Multiple thrombopoietin receptor agonists (TPO-RAs) have been approved for other thrombocytopenic indications, however, and are widely available, offering an accessible option for CIT management. In this Research and Practice in Thrombosis and Haemostasis Forum article, the historical reasons for the current state of CIT treatment are explained, the potential benefits and risks of TPO-RA use in CIT are discussed, and the patient populations who are likely to benefit and not benefit from TPO-RA support are described.
化疗引起的血小板减少症（CIT）是实体瘤癌症治疗常见的并发症，会导致出血风险增加以及化疗剂量减少、治疗延迟和药物停用。与其他化疗引起的血细胞减少症不同，在世界上大多数地区，CIT仍然没有任何获批的治疗方法。然而，多种血小板生成素受体激动剂（TPO-RAs）已被批准用于其他血小板减少症适应症，并且广泛可得，为CIT的管理提供了一个可及的选择。在这篇发表于《血栓与止血研究与实践论坛》的文章中，解释了CIT治疗现状的历史原因，讨论了在CIT中使用TPO-RA的潜在益处和风险，并描述了可能从TPO-RA支持中获益和未获益的患者群体。
